New Dual Artificial Pump- Still in Development
Tandem is in partnership with the JDRF to develop a dual hormone pump which will continue to be funded, as Tandem reaches different milestones. Once approved by the FDA, this novel and groundbreaking medical device will have two hormone chambers. One chamber for insulin, the second chamber for a different hormone that supports different therapies. “At this time, insulin is the only approved hormone for an insulin pump,” says Susan Morrison, Chief Administrative Officer from Tandem Diabetes Care.
How does the pump work?
The new dual hormone pump will have two chambers for two infusion sets and one sensor. Each infusion set will connect to a different chamber; Conceivably, both insulin and Glycogen.
The insulin hormone will release from the chamber if the blood glucose level is higher than desired. If insulin is too low: glucagon will be released
to increase blood sugar levels.
On the research side, the idea is to get a fully closed loop artificial pancreas. There are many researchers who feel you cannot get there with insulin alone. If you add anther hormone to insulin then the ability to have a closed looped system will work” says Mike Rosinko, VP of research and development Officer from Tandem Diabetes Care.
“A launch date has not been set” for the new dual artificial pump.”
We have to figure out the regulatory path where we sit down and have a discussion with the FDA to insure what the agencies expectations are. Clinical trials first, then moving forward, once the requirements have been met, a realistic launch can be determined. Says Susan Morrison, Chief Administrative Officer from Tandem Diabetes Care.
